Bruce Cozadd - Jazz Pharmaceuticals Insider

J7Z -- Germany Stock  

EUR 149.00  0.00  0.00%

Chairman of the Board, CEO
Mr. Bruce C. Cozadd is a Chairman of the Board, Chief Executive Officer of Jazz Pharmaceuticals PLC. He has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012. He cofounded Jazz Pharmaceuticals, Inc. and has served as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.s Executive Chairman and as a member of its board of directors. From 1991 until 2001, he held various positions with ALZA Corporationrationration, a pharmaceutical company acquired by Johnson Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporationrationration, he held the roles of Chief Financial Officer and Vice President, Corporationrationrate Planning and Analysis. He serves on the boards of directors and compensation committees of Cerus Corporationrationration, a biomedical products company, and Threshold Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, and on the boards of The Nueva School, a nonprofit organization, and SFJAZZ, a nonprofit organization. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. As our Chief Executive Officer, he brings to our board of directors a detailed knowledge of our business.
Age: 52  Chairman Since 2009  MBA    
353 1 634 7800

Bruce Cozadd Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 7.0 % which means that it generated profit of $7.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 18.75 % meaning that it generated $18.75 on every $100 dollars invested by stockholders.
The company has accumulated 1.58 B in total debt with debt to equity ratio (D/E) of 56.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Jazz Pharmaceuticals Public Limited Company has Current Ratio of 2.94 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. In addition, it evaluates deuterated oxybate for narcolepsy and sells psychiatry and other products. Jazz Pharmaceuticals operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 1230 people.Jazz Pharmaceuticals Public Limited Company (J7Z) is traded on Frankfurt Stock Exchange in Germany. It is located in Waterloo Exchange and employs 1,230 people.

Jazz Pharmaceuticals Leadership Team

Matthew Young, President, MBA
Paul Berns, Director
Iain McGill, President
Daniel Swisher, President, MBA
Suzanne Hooper, President
Rick Winningham, Director, MBA
Peter Gray, Director
Heather McSharry, Director
Michael Miller, President, MBA
Katherine Littrell, President
Paul Treacy, President
Patrick Enright, Director, MBA
Karen Wilson, President
Norbert Riedel, Director, Ph.D
Seamus Mulligan, Director
Russell Cox, President
Catherine Sohn, Director
Karen Smith, Executive, MBA
Elmar Schnee, Director
Kenneth OKeefe, Director, MBA
Bruce Cozadd, Chairman, MBA

Stock Performance Indicators

Current Sentiment - J7Z

Jazz Pharmaceuticals Investor Sentiment
Macroaxis portfolio users are indifferent in their judgment towards investing in Jazz Pharmaceuticals Public Limited Company. What is your judgment towards investing in Jazz Pharmaceuticals Public Limited Company? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.